Prime Medicine Inc PRME

Healthcare Biotechnology

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.

NDAQ:PRME - Post by User

Prime Medicine Inc

<< Previous

Bullboard Posts

Post by PivotStock22on Nov 26, 2024 6:36pm

20 Views

Post# 36332360

$PRME Testing Key Levels, $BOLT.CN Long Setup

$PRME is consolidating near 0.31, hovering just above support at 0.30. A breakout above 0.33 could unlock more upside—volume will be key. At the same time, $BOLT.CN looks primed for a long, as it continues to show strength in the market. Both worth watching.

<< Previous

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!